The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
Open accessAbstract
Huntington's disease (HD), an inherited neurodegenerative disorder, is caused by an abnormal polyglutamine expansion in the huntingtin protein. This genetic defect may result in heightened neuronal susceptibility to excitotoxic injury, a mechanism that has been postulated to play a critical role in HD. Quinolinate (QUIN) and kynurenate (KYNA), two endogenous neuroactive metabolites of the kynurenine pathway of tryptophan degradation, have been proposed to modulate excitotoxic neuronal death in HD. A third kynurenine pathway metabolite, the free radical generator 3-hydroxykynurenine (3-HK), has also been hypothesized to play a causal role in the pathogenesis of HD. We show here that the brain levels of both 3-HK and QUIN are increased three to four-fold in low-grade (grade 0/1) HD brain. These changes were seen in the neocortex and in the neostriatum, but not in the cerebellum. In contrast, brain 3-HK and QUIN levels were either unchanged or tended to decrease in grade 2 and advanced grade (grades 3-4) HD brain. Brain kynurenine and KYNA levels fluctuated only modestly as the illness progressed. These results support a possible involvement of 3-HK and QUIN in the early phases of HD pathophysiology and indicate novel therapeutic strategies against the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Self-citationEarly mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Free Radical Pathways in CNS Injury
LEWÉN, A., MATZ, P., & CHAN, P. H. (2000) · Journal of Neurotrauma · doi:10.1089/neu.2000.17.871 · Cited by 759
HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 680
Stipe, J., White, D., & Arsdale, E. V. (1979) · The American Journal of Nursing · doi:10.2307/3424618 · Cited by 602
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00615-3 · Cited by 595
Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities
Schwarcz, R., & Pellicciari, R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034439 · Cited by 556
Self-citation
Cited by
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?
Lewerenz, J., & Maher, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00469 · Cited by 718
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Self-citationMechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Self-citationKynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease
FAN, M., & RAYMOND, L. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.003 · Cited by 413
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Brouillet, E., Jacquard, C., Bizat, N., & Blum, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03515.x · Cited by 364
Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling
Gorman, A. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00402.x · Cited by 362
“Post-mortem analysis of the early stage HD patient brains indicates increased levels of the NMDA receptor agonist, quinolinic acid, and its precursor 3-hydroxy-kynurenine, suggesting that it may act as an endogenous excitotoxin in HD [116].”
An expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., & Muchowski, P. J. (2005) · Nature Genetics · doi:10.1038/ng1542 · Cited by 328
Self-citationRaymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
The kynurenine pathway and neurodegenerative disease
Maddison, D. C., & Giorgini, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.002 · Cited by 309
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Ryu, J. K., Choi, H. B., & McLarnon, J. G. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.04.010 · Cited by 93
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
Orhan, F., Bhat, M., Sandberg, K., Ståhl, S., Piehl, F., Karolinska Schizophrenia Project (KaSP) consortium, Svensson, C., Erhardt, S., & Schwieler, L. (2016) · Scandinavian Journal of Immunology · doi:10.1111/sji.12479 · Cited by 47
Assessment of cortical and striatal involvement in 523 Huntington disease brains
Hadzi, T. C., Hendricks, A. E., Latourelle, J. C., Lunetta, K. L., Cupples, L. A., Gillis, T., Mysore, J. S., Gusella, J. F., MacDonald, M. E., Myers, R. H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e9a5d · Cited by 46
Bioanalytical inaccuracy: A threat to the integrity and efficiency of research
Young, S. N., & Anderson, G. M. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.090171 · Cited by 31
Metadata
- Authors
- GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 17
- Issue
- 3
- Pages
- 455-461
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1971242889
- Cited by
- 260
- References
- 55
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.